SUMMARY In a double blind placebo controlled trial, 434 patients with suspected myocardial infarction were randomised to treatment with nifedipine (n = 217) or placebo (n = 217) within six hours from the onset of chest pain. During the treatment period of 48 hours, a 10 mg capsule containing nifedipine or placebo was given sublingually every four hours for 24 hours, then orally every four hours for the next 24 hours. Acute myocardial infarction was confirmed in 295 patients (146 in the nifedipine group and 149 in the placebo group). The median delay time to intervention with nifedipine in patients with acute myocardial infarction was 111 minutes. Infarct size was assessed by the estimation of release of creatine kinase isoenzyme MB and creatine kinase from blood samples taken every four hours for 48 hours. The total mean (SEM) creatine kinase MB released was 406-4 (27-2) IU/I in the nifedipine group and 345*7 (20 5) IU/l in the placebo group. Total mean (SEM) creatine kinase released was 2749-6 (165-1) IU/I in the nifedipine group and 2698-4 (145-9) IU/I in the placebo group. In hospital mortality was similar for both the nifedipine and placebo groups (6 6% and 5 8% respectively). Treatment with nifedipine in the early phase of acute myocardial infarction seems to have no effect on enzymatically measured infarct size. 
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Experiments in dogs suggest that nifedipine, a calcium channel blocking agent, can reduce the area of myocardial necrosis after coronary artery occlusion."o Nifedipine can reduce cardiac work, and therefore myocardial oxygen demand, by decreasing peripheral vascular resistance as a result of its strong peripheral vasodilatory effect. It can also increase coronary blood flow by coronary artery vasodilatation and improve collateral blood flow.' ' 4 At a cellular level, nifedipine has been shown to reduce intramitochondrial calcium overload. 4 The success of nifedipine as a means of reducing infarct size in dogs has not been reproduced in clinical studies. This is perhaps surprising, in view of the apparently beneficial haemodynamic effects of nifedipine in the early phase of acute myocardial infarction in man.7 Two Walker, MacKenzie, Adgey Several hours after entry to the study, when the effect of any narcotic analgesia had worn off, patients were asked whether they wished to remain in the study. Pulse and blood pressure were recorded every half hour for two hours, then the pulse was measured hourly and blood pressure every four hours while the patient remained in the coronary care unit. Routine investigations (for example blood gases and electrocardiograms) took place as usual in the coronary care unit.
Intravenous streptokinase was given to 44 patients in this study (27 3) . Multiple regression analysis showed no evidence ofa relation between the three baseline factors known to differ between treatment and placebo groups and in peak creatine kinase MB or total creatine kinase MB released.
Estimates of infarct size from creatine kinase were available in fewer patients than estimates from the creatine kinase MB isoenzyme, primarily because creatine kinase activity had sometimes not returned to baseline values by the end ofour 48 hour sampling period. This was the case in 10 (9-4%) patients in the treatment group and seven (5-8%) patients in the placebo group. In addition, we excluded results from patients in whom cardioversion was performed or in whom cardiogenic shock had developed or who received intramuscular injections, because these factors are known to interfere with creatine kinase activity. Total (291) (10-') and 7042 (277) (10-') in the placebo group. These values were not significantly different (Student's t test).
ASPARTATE TRANSAMINASE AND MYOGLOBIN
Patients were excluded from the analysis if cardioversion had been performed, if cardiogenic shock had developed, or if they had had intramuscular injections, because these factors are known to interfere with measurement ofaspartate transaminase and myoglobin. Peak mean (SEM) aspartate transaminase was 271 34 (17- The frequency of early ventricular fibrillation during the 48 hour study period, and of pulmonary oedema, reinfarction, and cardiogenic shock during Infarct sizes estimated by total creatine kinase MB released by different sites and types of myocardial infarction were compared. The number of patients was too small for meaningful analysis, except in patients with transmural myocardial infarction. In these patients, total mean (SEM) creatine kinase MB released was significantly larger (496-4 (32-0) IU/1) in the treatment group (n = 65), than in the placebo group (383-9 (24-4) IU/l) (n = 72).
Discussion
The 48 hour treatment regimen of nifedipine used in this study did not affect infarct size as measured by total creatine kinase MB released or total creatine kinase released. Nor did it have an effect on cruder indicators of infarct size, including peak activities of creatine kinase MB, peak creatine kinase, peak aspartate transaminase, and peak myoglobin concentration. These findings confirm the results of similarly designed studies by Muller et al8 and Sirnes et al,9 who suspected that the failure of nifedipine to limit infarct size was related to the relatively late intervention times in their studies (mean delay 4-6 hours and 5-5 hours respectively). This was not a feature of our study (mean total delay time in the treatment group was 2-3 hours). In a study by Branagan et al (1986) mean delay time to intervention with nifedipine was EAffect of nifedipine on infarct size in the early phase of acute myocardial infarction 409 3-3 hours but the number of patients in this study in whom infarct size was obtainable was too small for meaningful analysis (23 in the nifedipine treated group and 17 in the placebo group) and there was no difference between the groups reported.'3 Perhaps the dose and frequency of nifedipine used were suboptimal. But we were reluctant to expose patients to the hazard of excessive vasodilatation which could have resulted with larger doses of nifedipine. The dose ofnifedipine chosen had in any case been shown to produce favourable haemodynamic effects in acute myocardial infarction.7 This earlier study found that in patients treated with nifedipine cardiac output was significantly higher and peripheral vascular resistance significantly lower than in control patients. Logically this reduction in afterload should reduce myocardial oxygen demand because cardiac work is less and hence infarct size should be reduced.
WHY DOES NIFEDIPINE FAIL TO LIMIT INFARCT SIZE?
The apparent lack of effect of nifedipine on the limitation of infarct size may be related to the development of relative hypotension in some patients, which would offset any benefit. Such a phenomenon was seen in experimental studies by Selwyn et In conclusion, early intervention with nifedipine treatment in the acute phase ofmyocardial infarction appears to have no effect on infarct size as measured enzymatically by total creatine kinase MB released, total creatine kinase released, nor does it seem to have any impact on peak aspartate transaminase activity or peak myoglobin concentrations. In hospital mortality in treatment and placebo groups was not significantly different. The contrast in the efficacy of nifedipine in the experimental and clinical settings makes us doubt the value of experimental assessment of limitation of infarct size. 
